英文名稱 | Vonoprazan Fumarate | TAK-438 |
---|---|
中文名稱 | 富馬酸沃諾拉贊 | 富馬酸伏諾拉生| 1260141-27-2 |
CAS號(hào) | 881681-01-2 |
分子式 | C17H16FN3O2S· C4H4O4 |
分子量 | 461.46 | 345.39 (Free) |
外觀 | White to off-white powder |
儲(chǔ)存條件 | 4°C, sealed storage, away from moisture and light |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無(wú)牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Vonoprazan Fumarate | TAK-438 |
---|---|
中文名稱 | 富馬酸沃諾拉贊 | 富馬酸伏諾拉生| 1260141-27-2 |
CAS號(hào) | 881681-01-2 |
分子式 | C17H16FN3O2S· C4H4O4 |
分子量 | 461.46 | 345.39 (Free) |
外觀 | White to off-white powder |
儲(chǔ)存條件 | 4°C, sealed storage, away from moisture and light |
Vonoprazan Fumarate, also known as TAK438, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. TAKECAB provides a strong and sustained acid secretion inhibitory effect.
PMID: 22512618 DOI: 10.1021/jm300318t